Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

Recurrent Septicemia in an Immunocompromised Patient Due to Probiotic Strains of Bacillus subtilis

Marco Rinaldo Oggioni, Gianni Pozzi, Pier Egisto Valensin, Piero Galieni, Catia Bigazzi
Marco Rinaldo Oggioni
Sezione di Microbiologia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianni Pozzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Egisto Valensin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Galieni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catia Bigazzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.36.1.325-326.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Bacillus subtilis is a gram-positive, aerobic, spore-forming soil bacterium ubiquitous in the environment. The beneficial effects of B. subtilis spores on the balance of the intestinal microflora is the rationale for its general use as a probiotic preparation in the treatment or prevention of intestinal disorders. B. subtilis spores are available in Italy as a pharmaceutical preparation for oral use. Each dose contains a mixture of 109 spores of four distinct antibiotic-resistant derivatives of ATCC 9799 (Enterogermina; distributed by Sanofi Winthrop, Milan, Italy) (1, 4) per vial. The pathogenic potential ofB. subtilis is generally described as low or absent (2). Data on the general importance of infections due to B. subtilis are incomplete, since it is a general practice of most microbiological laboratories to discard these strains or to report them as contaminants. Also, in the cause-of-death statistics of the World Health Organization no data on B. subtilis infections are present since, even if reported, they would be “invisible” at the international comparative level due to the coding used for classification of death causes (2a). In the literature, only a few cases of infections due to B. subtilis are reported (3, 6-8, 10) and only one retrospective study describes the isolation of antibiotic-resistant strains of B. subtilis (6).

The subject of our report is a 73-year-old male with chronic lymphocytic leukemia (leukocyte count, 46,000/mmc with 4% segmented forms, 92% lymphocytes, and 4% monocytes) who was admitted to the hospital because of high fever (40°C), mental confusion, and diarrhea (through the period of hospitalization, the patient had no central line in place). Prehospitalization treatment (over a month) with B. subtilis spores (Enterogermina) (EG) was discontinued upon the patient’s admission to the hospital. On physical examination, the patient showed hepatosplenomegaly and multiple pulmonary thickenings were visible on the chest X ray. He had sluggish mentation and speech but no focal neurological deficits. Blood cultures performed in triplicate (on day 1) were positive for B. subtilis. Treatment with imipenem (days 1 to 16) apparently resolved the infectious episode, although mild fever persisted, possibly due to the lymphoproliferative disorder. After 2 weeks of hospitalization, the patient presented again with a high fever and mental confusion. Blood cultures were repeated (days 16 and 19), and B. subtilis was present in both cultures. Combined antibiotic therapy (ceftazidime, amikacin, and vancomycin, to all of which both strains were susceptible) was started, together with intravenously administered immunoglobulins, and the fever rapidly declined. Nevertheless, the patient showed progressive deterioration of his mental condition, still without focal neurological signs. At this stage, lymphoid cells were detected in the cerebrospinal fluid (cerebrospinal fluid was not cultured), and the patient died within a few days (day 25), probably due to central nervous system involvement.

The B. subtilis strains isolated during fever episodes on days 1 and 19 showed resistance to penicillin, erythromycin, rifampin, and novobiocin. The isolate from the blood culture on day 16 differed, being susceptible to rifampin and novobiocin and resistant to chloramphenicol. Due to the unusual pattern of resistance to antimicrobial agents (5), the three isolates were compared to theB. subtilis strains isolated from EG. Strains isolated on days 1 and 19 showed an antibiotic resistance profile identical to that of the rifampin- and novobiocin-resistant EG isolate (EG-RN), while the strain isolated at day 16 showed a resistance profile identical to that of the chloramphenicol-resistant EG strain (EG-CM). Strain typing by antibiogram was confirmed by two other lines of evidence. Biochemical profiles (API 50CH and API 20E; bioMérieux) distinguished the rifampin- and novobiocin-resistant clinical isolate and the EG-RN strain (gelatinase negative) from the chloramphenicol-resistant clinical isolate and the EG-CM strain (gelatinase positive). The randomly amplified polymorphic DNA technique (9) clearly confirmed the clonal difference, evidencing distinctive DNA amplification patterns for the chloramphenicol-resistant strains and for the rifampin- and novobiocin-resistant strains (Fig. 1).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Ethidium bromide-stained agarose gel of randomly amplified fragments of B. subtilis chromosomal DNA. Amplification was performed with primer GTTTCCGCCC as described in reference 9. Lane 1, rifampin- and novobiocin-resistant clinical isolate; lane 2, EG-RN strain; lane 3, chloramphenicol-resistant clinical isolate; lane 4, EG-CM strain; lane 5, B. subtilis ATCC 6633; lane 6, B. subtilisreference strain Marburg; lane 7, molecular weight standard (phage ΦX174 cut with restriction enzyme HaeIII).

The described recovery of two different Bacillus strains from the same probiotic preparation in distinct septicemic episodes is indicative both of the severe immunodeficiency of the patient and of a persistence of the microorganism in the intestinal tract, a property already described for strain EG-RN (4). This report, as does a report describing typing of strains by antibiogram only (6), documents the high risk to which severely immunocompromised patients can be exposed when treated with pharmaceutical products based on live microorganisms. We conclude that, even if the septicemia due to the probiotic strains of B. subtilis could not be related directly to the patient’s death, high numbers of viable microorganisms (especially if polyantibiotic resistant) should not be given to any patient with severe immunodeficiency.

  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Ciffo F.
    Determination of the spectrum of antibiotic resistance of the Bacillus subtilis strains of Enterogermina.Chemioterapia 3 1984 45 52
    OpenUrlPubMedWeb of Science
  2. 2.↵
    1. de Boer A. S.,
    2. Diderichsen B.
    On the safety of Bacillus subtilis and B. amyloliquefaciens: a review.Appl. Microbiol. Biotechnol. 36 1991 1 4
    OpenUrlPubMed
  3. 2a.↵
    Frank, O. (World Health Organization). Personal communication.
  4. 3.↵
    1. Kiss T.,
    2. Gratwohl A.,
    3. Frei R.,
    4. Osterwalder B.,
    5. Tichelli A.,
    6. Speck B.
    Bacillus subtilis infections.Schweiz. Rundsch. Med. Prax. 77 1988 1219 1223
    OpenUrlPubMed
  5. 4.↵
    1. Mazza P.,
    2. Zani F.,
    3. Martelli P.
    Studies on the antibiotic resistance of Bacillus subtilis strains used in oral bacteriotherapy.Boll. Chim. Farm. 131 1992 401 408
    OpenUrlPubMed
  6. 5.↵
    1. Reva O. N.,
    2. Vyunitskaya V. A.,
    3. Reznik S. R.,
    4. Kozachko L. A.,
    5. Smirnov V. V.
    Antibiotic susceptibility as a taxonomic characteristic of the genus Bacillus.Int. J. Syst. Bacteriol. 45 1995 409 411
    OpenUrlCrossRefPubMed
  7. 6.↵
    1. Richard V.,
    2. Van der Auwera P.,
    3. Snoeck R.,
    4. Daneau D.,
    5. Meunier F.
    Nosocomial bacteremia caused by Bacillus species.Eur. J. Clin. Microbiol. Infect. Dis. 7 1988 783 785
    OpenUrlCrossRefPubMedWeb of Science
  8. 7.↵
    1. Thomas M.,
    2. Whittet H.
    Atypical meningitis complicating a penetrating head injury.J. Neurol. Neurosurg. Psychiatry 54 1991 92 93
    OpenUrl
  9. 8.↵
    1. Velasco E.,
    2. De Sousa Martins C. A.,
    3. Tabak D.,
    4. Bouzas L. F.
    Bacillus subtilis infection in a patient submitted to a bone marrow transplantation.Rev. Paul. Med. 110 1992 116 117
    OpenUrlPubMed
  10. 9.↵
    1. Vettori C.,
    2. Paffetti D.,
    3. Pietramellara G.,
    4. Stotzky G.,
    5. Gallori E.
    Amplification of bacterial DNA bound on clay minerals by the random amplified polymorphic DNA (RAPD) technique.FEMS Microbiol. Ecol. 20 1996 251 260
    OpenUrlCrossRef
  11. 10.↵
    1. Wallet F.,
    2. Crunelle V.,
    3. Roussel-Delvallez M.,
    4. Furchard A.,
    5. Saunier P.,
    6. Courcol R. J.
    Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease.Am. J. Gastroenterol. 91 1996 1477 1478
    OpenUrlPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Recurrent Septicemia in an Immunocompromised Patient Due to Probiotic Strains of Bacillus subtilis
Marco Rinaldo Oggioni, Gianni Pozzi, Pier Egisto Valensin, Piero Galieni, Catia Bigazzi
Journal of Clinical Microbiology Jan 1998, 36 (1) 325-326; DOI: 10.1128/JCM.36.1.325-326.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Recurrent Septicemia in an Immunocompromised Patient Due to Probiotic Strains of Bacillus subtilis
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Recurrent Septicemia in an Immunocompromised Patient Due to Probiotic Strains of Bacillus subtilis
Marco Rinaldo Oggioni, Gianni Pozzi, Pier Egisto Valensin, Piero Galieni, Catia Bigazzi
Journal of Clinical Microbiology Jan 1998, 36 (1) 325-326; DOI: 10.1128/JCM.36.1.325-326.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Bacillus subtilis
bacteremia

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X